3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Myeloproliferative Disorders
9
Primary Myelofibrosis
8
Pancreatic Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Leukemia, Myeloid, Acute
4
Leukemia
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Thrombocythemia, Essential
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thrombocytosis
1
Squamous Cell Carcinoma of Head and Neck
1
Polycythemia Vera
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
ruxolitinib
1
eltrombopag
1
Doxorubicin
1
Docetaxel
1
Cytarabine
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Pathologic Complete Response
×
ruxolitinib
×
Clear all
NCT04934670
2024-08-27
2002
Xenikos
Phase 3
Terminated
12 enrolled
12 charts